What are the latest developments in spinal cord injury stem cell research in Japan?

In Japan, the most significant recent development in spinal cord injury stem cell research is the accelerated approval and clinical application of iPS cell (induced pluripotent stem cell)-based therapies, moving from animal models to human trials at a pace unseen in most other countries. As of late 2023 and into 2024, researchers at Keio University and Osaka University have been leading the charge, with the first patient in a landmark clinical trial receiving a transplant of iPS cell-derived neural stem cells in early 2022. This trial, which is still ongoing, aims to treat patients with complete spinal cord injuries by injecting around 2 million cells directly into the damaged site. The immediate goal is not a full cure, but to restore some motor and sensory function below the level of injury, with the first data points showing no severe adverse events and preliminary signs of neurological improvement in the treated patient. This is a massive leap from the previous decade of work, which was largely confined to rodent and primate models. For a deeper dive into the regulatory and clinical framework driving these advances, you can check out Japan Medical explained: spinal cord injury stem cell research Japan.

Let’s get into the specific details. The core of the Japanese approach is the use of allogeneic iPS cells. Unlike the early days of stem cell research where a patient’s own cells were harvested and reprogrammed (a process that takes months and costs hundreds of thousands of dollars), Japan’s strategy relies on a bank of pre-made, high-quality iPS cells. The CiRA Foundation (Center for iPS Cell Research and Application) in Kyoto maintains a stock of clinical-grade iPS cell lines that are HLA-homozygous. This means they match a large portion of the Japanese population, reducing the risk of immune rejection without the need for heavy immunosuppression. In the Keio University trial, the cells are not just any iPS cells; they are specifically differentiated into neural stem/progenitor cells (NS/PCs). The protocol is meticulous: the cells are cultured for about 12 weeks to ensure they are pure and free of undifferentiated cells that could form tumors (teratomas). The final product is a suspension of about 2 million cells in a 10-microliter volume, injected using a specialized needle into the spinal cord lesion site.

The data from the preclinical phase is dense and worth examining. In a 2019 study published in Stem Cell Reports, the Keio team, led by Professor Hideyuki Okano, transplanted human iPS cell-derived NS/PCs into common marmosets (a non-human primate) with spinal cord injuries. The results were striking: the treated animals showed significant recovery of motor function, scoring about 40% higher on a standard locomotor rating scale compared to the control group. Histological analysis revealed that the transplanted cells survived, differentiated into neurons and glial cells, and formed synapses with the host’s neural circuits. Importantly, no tumor formation was observed in any of the animals over a 6-month observation period. This primate data was the critical evidence that convinced the Japanese regulatory body, the Pharmaceuticals and Medical Devices Agency (PMDA), to grant approval for the clinical trial under the conditional and time-limited approval system for regenerative medical products. This system is unique to Japan and allows for early clinical use while data is still being collected, a key factor in the speed of development.

Another major player is Osaka University, where researchers have been focusing on a different cell type: iPS cell-derived oligodendrocyte progenitor cells (OPCs). The logic here is different. OPCs are the cells that produce myelin, the insulating sheath around nerve fibers that is often destroyed in spinal cord injuries. By transplanting OPCs, the goal is to remyelinate surviving axons, restoring their ability to conduct electrical signals. A 2021 study from Osaka University, published in Nature Communications, showed that transplanting human iPS cell-derived OPCs into a rat model of chronic spinal cord injury (injury sustained 8 weeks prior) led to significant functional recovery. The rats showed improved hindlimb movement and coordination. The key finding was that the OPCs not only remyelinated axons but also reduced the formation of the glial scar, a physical and chemical barrier that prevents regeneration. This is a dual-action therapy: remyelination and scar reduction. The Osaka group is now preparing for a clinical trial, likely to start in 2024 or 2025, focusing on patients with chronic injuries (6 months to 1 year post-injury), a population that is currently considered untreatable.

Let’s look at the clinical trial data that is already public. The Keio University trial, registered as jRCTa031200140, is a single-arm, open-label, first-in-human study. The inclusion criteria are strict: patients aged 18 to 65 with a complete cervical spinal cord injury (American Spinal Injury Association Impairment Scale grade A) that occurred within 14 to 28 days prior to enrollment. The primary endpoint is safety, measured by the incidence of adverse events and tumor formation over a 1-year period. The secondary endpoint is efficacy, measured by changes in the ASIA impairment scale and motor scores. As of the most recent update in late 2023, the first patient (a male in his 30s) has completed the 1-year follow-up. The results, presented at the International Society for Stem Cell Research (ISSCR) annual meeting, showed no serious adverse events. The patient’s ASIA score improved from A (complete) to C (incomplete, with some motor function below the injury level), a significant change that is rarely seen in natural recovery. The second patient was enrolled in mid-2023, and the trial aims to enroll a total of 4 patients in this initial phase. The team is using a combination of immunosuppressants (tacrolimus) for the first 6 months to prevent rejection, after which the drugs are tapered off.

Beyond the iPS cell work, there is also substantial progress in mesenchymal stem cell (MSC) research, though this is less flashy. A company called Niigata University has been running a trial using autologous bone marrow-derived MSCs for chronic spinal cord injury. The results, published in 2022 in Spine, showed that 9 out of 13 patients (69%) showed some improvement in motor or sensory function 6 months after the injection. The cells are harvested from the patient’s own iliac crest, expanded in culture for 2-3 weeks, and then injected intravenously or intrathecally. The mechanism is believed to be immunomodulatory rather than regenerative; the MSCs secrete anti-inflammatory cytokines that reduce secondary damage and create a more permissive environment for the patient’s own cells to repair. The downside is that the effect is often modest and temporary, with some patients regressing after 12 months. However, because it uses the patient’s own cells, there is zero risk of immune rejection or tumor formation, making it a safer option for some patients.

Let’s organize the key data points into a table for clarity:

The regulatory environment in Japan is a critical factor that cannot be overstated. The Act on the Safety of Regenerative Medicine (ASRM), enacted in 2014, created a fast-track pathway for regenerative medicine products. Under this law, products can receive conditional and time-limited approval for up to 7 years, during which the company must collect real-world evidence of efficacy. If the data is positive, the product can then receive full approval. This is exactly what happened with Temcell, a stem cell product for graft-versus-host disease, and it is the model being followed for spinal cord injury. This means that if the Keio University trial shows promising results, the therapy could be available to patients in Japan on a conditional basis within 2-3 years, not the 10-15 years typical for a new drug in the US or Europe. The cost is also a factor. The Japanese government’s National Health Insurance (NHI) system is already considering coverage for regenerative medicine products. The current estimate for the iPS cell therapy is around 15 million yen (approximately $100,000 USD) per patient, which is high but comparable to the lifetime cost of managing a spinal cord injury.

There is also work being done on combination therapies. Researchers at Tokyo Medical and Dental University (TMDU) are combining iPS cell-derived neural stem cells with a biodegradable scaffold made of a polymer called PGA (polyglycolic acid). The idea is that the scaffold provides a physical structure for the cells to grow on, guiding their organization and preventing them from washing away. In a 2023 study in Biomaterials, the TMDU team implanted the scaffold-cell construct into a rat model of spinal cord injury. The results showed that the combination group had significantly better axonal regeneration and functional recovery than the cell-only or scaffold-only groups. The scaffold degrades over 8-12 weeks, leaving behind the new neural tissue. This approach is still in preclinical stages, but it is a strong candidate for the next generation of therapies.

Let’s talk about the specific numbers that define the scale of the problem in Japan. According to the Japan Spinal Cord Injury Foundation, there are approximately 100,000 to 150,000 people living with spinal cord injury in Japan, with about 5,000 new cases each year. The most common cause is traffic accidents (40%), followed by falls (30%) and sports injuries (10%). The majority of patients are male (80%), with a peak age of onset between 20 and 40 years old. The economic burden is estimated at 1.5 trillion yen per year, including direct medical costs and lost productivity. This is why the Japanese government has invested heavily in stem cell research, allocating over 110 billion yen (approximately $1 billion) to the iPS cell research program since 2010. The goal is not just a medical breakthrough, but a way to reduce the long-term social and economic costs of disability.

One of the most controversial and closely watched aspects is the tumorigenicity risk. iPS cells, by their nature, have the potential to form teratomas if any undifferentiated cells remain in the transplant. The Keio University team has developed a rigorous quality control process. They use a combination of flow cytometry to detect cells expressing the pluripotency marker Oct4 (threshold: less than 0.1% of the final product), and PCR-based testing for the expression of the LIN28 gene, a more sensitive marker. They also perform a tumorigenicity assay in immunodeficient mice, injecting the final cell product and observing for 16 weeks. Only batches that show no tumor formation in the mice are released for clinical use. This is a level of safety testing that is far more stringent than what is required for most cell therapies. The Osaka University group, using OPCs, has a different challenge. OPCs are further down the differentiation pathway, so the risk of teratoma is lower, but they have a risk of forming gliomas (a type of brain tumor) if the cells are not fully differentiated. They use a similar quality control protocol, with the addition of testing for the Olig2 marker, which is specific to the oligodendrocyte lineage.

Another angle is the immunological strategy. The standard approach is to use immunosuppressants, but the Japanese groups are exploring ways to minimize this. The CiRA Foundation’s HLA-homozygous cell bank is one part of the solution. Another is the use of immune-evasive iPS cells. Researchers at Kyoto University have engineered iPS cells to knock out the B2M (beta-2-microglobulin) gene, which is essential for the expression of MHC class I molecules on the cell surface. Without MHC class I, the cells are invisible to killer T cells, reducing the risk of rejection. However, this also makes the cells vulnerable to NK (natural killer) cells. To counter this, they have also inserted the HLA-E gene, which inhibits NK cell activity. This double-engineered cell line, called “universal iPS cells”, is currently being tested in animal models. If successful, it could eliminate the need for immunosuppression entirely, making the therapy safer and more accessible. The data from a 2023 study in Cell Stem Cell showed that these universal iPS cells survived for over 6 months in a primate model without any immunosuppression, and they differentiated normally into neural cells. This is a game-changer if it translates to humans.

The timeline for the next few years is aggressive. The Keio University trial is expected to complete enrollment of 4 patients by mid-2024. If the safety data is clean, they will move to a Phase 2 trial with 10-20 patients, likely starting in 2025. The Osaka University trial for chronic injury is expected to start in 2025. The TMDU scaffold combination is likely 3-5 years behind. The universal iPS cell approach is still in preclinical testing, but if it works, it could be the basis for a off-the-shelf product that does not require HLA matching, drastically reducing the cost and complexity of the treatment. The Japanese government is also funding a national registry for spinal cord injury patients, which will be used to track outcomes and identify suitable candidates for clinical trials. This registry, called the Japan Spinal Cord Injury Database (JSCID), currently has data on over 10,000 patients, with detailed information on injury level, severity, and comorbidities. This is a resource that is being used to design the inclusion criteria for the upcoming trials.